•Claris Bio raises $118M to advance first-ever LSCD therapy•Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt•Pediatric cataract surgery carries greater endophthalmitis risk•ICO partners with Deya Imaging on AI model training study•EVOQ Technologies receives US patent for mobile retinal function testing•Claris Bio raises $118M to advance first-ever LSCD therapy•Belite Bio presents updated phase 3 data on oral tinlarebant for Stargardt•Pediatric cataract surgery carries greater endophthalmitis risk•ICO partners with Deya Imaging on AI model training study•EVOQ Technologies receives US patent for mobile retinal function testing
HEADLINES
RESEARCH
NSAID use may lower AMD risk
![[object Object]](/_next/image/?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F51cpf7jm%2Fproduction%2F0fbac34bad6d09f82e441f0027ebe861bc590ab8-1200x628.png%3Fw%3D2400%26q%3D100%26fit%3Dfill%26auto%3Dformat&w=3840&q=75)
FEATURED
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
